Laboratory-acquired Rocky Mountain spotted fever. The hazard of aerosol transmission.
Nine patients with laboratory-acquired Rocky Mountain spotted fever were seen during the period 1971 to 1976. Investigation of each case revealed either definite or probable exposure to an aerosol containing infectious rickettsiae; in no case was there evidence of parenteral exposure either by accidental self-inoculation or by tick bite. These illnesses are believed to represent infection acquired via the respiratory route. This report emphasizes the aerosol hazard of Rickettsia rickettsii in the laboratory and discusses the possibility of respiratory transmission of Rocky Mountain spotted fever in nature. The illness occurred only in personnel who had received either no vaccination or the primary series of the commercial (Lederie) vaccine against this infection. Other personnel who had received the primary series with multiple booster vaccinations demonstrated increased immunity as measured by humoral antibody titers and rickettsial antigen-induced lymphocyte transformation; no cases of clinical disease developed in these multiply-vaccinated personnel.
D000328:Adult; D000336:Aerosols; D000818:Animals; D000906:Antibodies / Q000032:analysis; D003168:Complement Fixation Tests; D006168:Guinea Pigs; D006801:Humans; D007114:Immunization / Q000379:methods; D007757:Laboratory Infection / Q000635:transmission*; D008213:Lymphocyte Activation; D008297:Male; D012189:Retrospective Studies; D012284:Rickettsia rickettsii / Q000276:immunology; D012290:Rickettsial Vaccines / Q000627:therapeutic use; D012306:Risk; D012373:Rocky Mountain Spotted Fever / Q000276:immunology / Q000517:prevention & control / Q000635:transmission*
D000336:Aerosols; D000906:Antibodies; D012290:Rickettsial Vaccines